Cytokinetics to Present Key Aficamten Data at HFSA 2026
Event summary
- Cytokinetics to present four data sets on aficamten at HFSA 2026, including two late-breaking clinical trial results
- Presentations focus on non-obstructive hypertrophic cardiomyopathy (nHCM) and obstructive HCM (oHCM)
- Key data from ACACIA-HCM and SEQUOIA-HCM trials to be unveiled October 9-12 in Phoenix
- Company plans Q4 2026 sNDA submission for aficamten in nHCM following positive topline ACACIA-HCM results
The big picture
Cytokinetics is positioning aficamten as a potential cornerstone therapy for both obstructive and non-obstructive hypertrophic cardiomyopathy. The HFSA presentations represent a critical validation opportunity as the company seeks to expand its only marketed product's indications. Success in nHCM could significantly increase aficamten's commercial potential in a currently underserved patient population.
What we're watching
- Regulatory Pathway
- Whether Q4 2026 sNDA submission timeline for aficamten in nHCM can be maintained following HFSA data presentation
- Market Expansion
- How nHCM indication approval could expand aficamten's addressable market beyond current oHCM patient population
- Clinical Efficacy
- The magnitude of exercise performance improvements shown in ACACIA-HCM data and their potential impact on prescribing patterns